Generics Group Cries Foul Over Biosimilar Exclusivity Provision in USMCA Trade Deal

A provision in the proposed U.S.-Mexico-Canada Agreement that would give branded biologics makers a decade of exclusivity goes against the White House’s stated priority of improving access to biosimilars, according to the Association for Accessible Medicines (AAM).
Source: Drug Industry Daily

No announcement available or all announcement expired.